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Sphingolipids are a family of lipids that play essential roles both as structural cell membrane components and in cell signalling. The cellular
contents of the various sphingolipid species are controlled by enzymes involved in their metabolic pathways. In this context, the discovery of
small chemical entities able to modify these enzyme activities in a potent and selective way should offer new pharmacological tools and
therapeutic agents.
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Sphingolipids (SLs) are a family of lipids that play essential
roles as structural cell membrane components and also in cell
signalling. From a structural standpoint, SLs derive from
sphingosine (Sph), a long chain amino alcohol, which is
acylated with a long chain fatty acid to give ceramides (Cer), the
central core of glycosphingolipids (GSLs) and sphingomyelin
(SM). Living cells contain several Cer and Cer metabolite
species differing in the length and degree of unsaturation of
their acyl chain, which appears to be relevant to their biological
activities. Although SLs have been classically related to cell
permeability, their roles in cell signalling and intercellular
communication are well recognized. Moreover, abnormal SLs
metabolism is nowadays known to occur in some diseases, such
as, inter alia, certain sphingolipidoses [1], cancer [2], diabetes
[3], and atherosclerosis [4]. As it will be discussed next, the
cellular contents of the various SLs species are controlled by
enzymes involved in their metabolic pathways. In this context,
the search for potent and selective inhibitors of these enzymes
offer new insights for the discovery of therapeutic agents.
2. Biosynthesis of ceramide: inhibitors of the de novo pathway
Cer is the central molecule in SLs and GSLs biosynthesis.
There are twometabolic routes leading to Cer: the anabolic or the
de novo pathway and the catabolic one. The first one comprises a
series of enzymatic processes leading ultimately to Cer from
simple components, such as palmitoyl CoA and serine (SectionsFig. 1. Biosynthesis of Cer2.1 Sections 2.2 Sections 2.3), whereas the catabolic route leads
to Cer from hydrolysis of complex SLs, mainly SM (Section 3.1)
and GSLs (Section 3.3.2) (Fig. 1).
2.1. Serine palmitoyltransferase
Serine palmitoyltransferase (SPT) catalyzes the first step in
the biosynthesis of sphingolipids, which is the condensation of
serine and palmitoyl CoA to produce 3-ketodihydrosphingosine
[5]. SPT is a member of a pyridoxal phosphate-dependent α-
oxoamine synthase family. The mammalian enzyme is a
heterodimer of two subunits, LCB1 and LCB2, both of which
are located in the endoplasmic reticulum. Specific missense
mutations in the human subunit LCB1 gene cause hereditary
sensory neuropathy type I. Inhibitors of SPT include sphingo-
fungins, lipoxamycin and myriocin (Fig. 2), which are natural
products with potent and highly selective activity. It has been
suggested that inhibition occurs by reaction of these compounds
with SPT to form adducts that mimic the natural intermediates
of the catalytic reaction [5].
The relevance of sphingofungin B stereochemistry to SPT
inhibitory activity was demonstrated by examining the effect of
several stereoisomers (Fig. 3) on sphingolipid biosynthesis both
in cell free extracts and in intact cells. They inhibited
sphingolipid biosynthesis in the order 2S,3R,4R,5S,14R=2S,
3R,4R,5S,14S≫2R,3R,4R,5S,14R>2S,3S,4R,5S,14R ≈2S,
3R,4R,5S > 2R,3S,4R,5S,14R≈ 2R,3S,4S,5R,14R≈2S,
3R,4S,5R,14R [6]. These results indicate that although the
C-14 hydroxyl group of sphingofungin B confers potent SPT: the de novo pathway.
Fig. 3. Stereoisomers of sphingofungin B.
Fig. 2. Inhibitors of SPT.
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the configurations of the stereogenic centers at positions α, β, γ
and ∂with respect to the carboxyl group are important to activity.
Viridiofungins are also SPT inhibitors of natural origin [7].
They are less potent and specific that sphingofungins and
myriocin, since they also inhibit other enzymes sensitive to di-
and tricarboxylic acids, such as squalene synthase [8]. Further-
more, viridiofungins do not inhibit Saccharomyces SPT, but they
do inhibit this enzyme in Candida albicans [7]. Two other
compounds that have been extensively used as SPT inhibitors are
L-cycloserine andβ-chloro-L-alanine (Fig. 2). Nevertheless, these
two chemicals inhibit several other pyridoxal phosphate-
dependent enzymes [9,10].
2.2. Ceramide synthase
Ceramide synthase (CerS) catalyzes the acylation of the
amino group of Sph, sphinganine and other sphingoid bases
using acyl CoA esters of varying chain lengths. CerS activity is
found both inmicrosomes [11] andmitochondria [12]. Inhibition
of CerS by several fungi metabolites has been reported, which
include Fumonisins [13], the fumonisin-relative AAL-toxin [14]
(Fig. 4) and australifungins [15] (Fig. 5). The fumonisins family
are produced by Fusarium verticillioides and Fumonisin B1
(FB1) is the most prevalent member of this class of compounds.
FB1 contains an aminoeicosapentol backbone with two
hydroxyl groups esterified with 3-carboxy-1,5-pentanedioic
acid. A similar structure is present in AAL-toxin, produced by
the fungus Alternaria alternata var. lycopersici. Several studies
[16] suggest that inhibition occurs because CerS recognizes the
aminopentol moiety (Fig. 4), which competes for binding to the
sphingoid base substrate, as well as the dicarboxylic acid side
chains, which act as analogs of fatty acyl-CoA phosphate groupsand interfere the binding of the acyl donor with the catalyst. The
O-deacylated form of FB1 is a weak CerS inhibitor. However, it
is also a substrate of CerS and its N-acylated forms are potent
CerS inhibitors [16]. This sequence of metabolic transforma-
tions may occur in vivo and play a role in the diseases caused by
fumonisins. In this regard, these N-acylated forms conform a
new category of ceramide synthase inhibitors. Structure-
function relationship studies showed that both erythro- and
threo-2-amino-3-hydroxy- and all (2S) stereoisomers of 2-
amino-3,5-dihydroxyoctadecanes (Fig. 4) are CerS inhibitors
and are acylated by CerS with the highest apparent Vmax/Km for
the 2S,3R analogues.
FB1 inhibits fungal CerS in vitro, but its activity in whole
cells is very weak, probably due to deficient internalization. In
contrast, australifungin (Fig. 5), a micotoxin isolated from
Sporormiella australis, is a very potent inhibitor of fungal CerS
from several species. However, both the alpha-diketone and
beta-ketoaldehyde functional groups present in this compound
confer australifungin a high chemical reactivity, which limits its
use [15].
Fig. 4. Fumonisin and related compounds as CerS inhibitors.
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Dihydroceramide desaturase (DES) is the last enzyme in the
de novo biosynthesis of ceramide [17]. Two different dihy-
droceramide desaturases, DES1 [18] and DES2 [19], have been
so far reported. Although their amino acid sequences have high
identity, they differ in their enzymatic characteristics, since
while DES1 exhibits high dihydroceramide desaturase activity
and very low C-4 hydroxylase activity, DES2 is similarly active
as both a dihydroceramide desaturase and a C-4 hydroxylase
(Fig. 6).
The cyclopropene-containing sphingolipid GT11 (Fig. 7) is a
competitive inhibitor of DES [20,21]. Structure–activity correla-
tion studies [21,22] showed that the natural 2S,3R stereochem-
istry, the amide function, the presence of a cyclopropene ring in
place of the ceramide double bond and a free hydroxyl group at
C1 are required for inhibition, as evidenced from comparison of
GT11 with C1-modified analogues GT34, GT37, and GT30 (Fig.
7) [21]. Furthermore, the α-ketoamide (GT85, GT98, and GT99),
urea (GT55) and thiourea (GT77) analogues (Fig. 7) retain
inhibitory activity, whereas the respective carbamate (GT45) was
inactive [22]. Likewise, N-methyl substitution of GT11 (com-
pound GT54) results in the loss of inhibitory activity [22]. The
ineffectiveness of carbamate andmethylamido derivativesmay be
due to interference with hydrogen bonding events required forFig. 5. Australifungin.inhibition, (i.e. enzyme–inhibitor interactions or arrangement of
the inhibitor into the active conformation).
In primary cultured neurons, GT11 inhibits dihydroceramide
desaturase in a concentration dependent manner (IC50 of 23 nM)
with a potency by three orders of magnitude higher than that
found in vitro [23]. However, although this inhibitory effect is
specific at concentrations up to 1 μM, higher concentrations
(from 5 μMupwards) of GT11 not only abolishes desaturation of
dihydroceramide, but also impairs de novo sphingolipid biosyn-
thesis by an indirect suppression of SPT activity. Metabolic
studies with radioactively labeled GT11 analogs indicated that the
inhibitor is subjected to catabolism by ceramidases (CDases) to
yield the cyclopropene-bearing long chain base [23]. Although
the free cyclopropene base does not inhibit dihydroceramide
desaturase [23], it cannot be completely disregarded that
deacylated GT11 or its phosphate are involved in the effect of
high concentrations of GT11. Further studies are needed to clarify
the mechanism underlying the effects of high concentrations of
GT11 in cultured cells.
Two dihydroceramide analogues with different alkyl chain
lengths have been prepared, in which the 3-hydroxy group has
been replaced by a fluorine atom (Fig. 8). Theywere investigatedFig. 6. Activities of dihydroceramide desaturases DES1 and DES2.
Fig. 7. GT11 and analogues as DES inhibitors.
Fig. 8. Dihydroceramide analogues as DES inhibitors.
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[24].
A dihydroceramide analogue with a cyclopropane ring at C-5
and C-6 of the sphinganine backbone has been reported as a
putative suicide inhibitor of the dihydroceramide desaturase (Fig.
8) [25]. The authors do not specify the configuration of the
cyclopropane stereogenic centers. They postulate that the C4
reactive intermediate generated in the first step of the desatura-
tion reaction [26] binds covalently to an amino acid side chain of
the desaturase, thus inhibiting the enzyme irreversibly, and
leading to the covalent modification of the protein.
Finally, in a recent article Schulz et al. have suggested that 4-
hydroxyfenretinide is an inhibitor of dihydroceramide desatur-
ase [27].
3. Biosynthesis and catabolism of sphingolipids: the pivotal
role of ceramide
Cer plays a central role in SLs biosynthesis. As depicted in Fig.
9, Cer can arise either from simple components in the so called de
novo biosynthesis (Section 2), from reacylation of Sph produced
by catabolic processes (“salvage pathway”), degradation of SM
through the “sphingomyelin cycle” or GlcCer hydrolysis. In all
cases, the reverse anabolic pathways converting Cer to the above
precursors also occur. Thus, the overall metabolic processes
around Cer compose an intricate scenario in which several
enzymes are implicated in the forward and reverse steps, offering
excellent targets for therapeutic intervention.
3.1. Inhibitors of the sphingomyelin cycle
SM is the primary sphingophospholipid in mammalian cells.
As much as two thirds of the total cellular SM resides at the
plasma membrane, where it plays important structural and
functional roles. The major pathway for SM synthesis is
catalyzed by the phosphatidylcholine:ceramide phosphocholine
transferase (sphingomyelin synthase; SMS), which transfers the
phosphocholine group from phosphatidylcholine to ceramide to
generate sphingomyelin and diacylglycerol (DAG). This
enzyme has the important ability to directly regulate, in
opposite directions, ceramide and DAG levels within the
cells, potentially controlling opposite cellular processes such ascell proliferation, growth arrest, and apoptosis [28]. SMS is an
integral membrane enzyme located in the Golgi apparatus.
Despite its importance in sphingolipid metabolism, SMSs-
encoding cDNAs have only been recently identified [29–31].
Compound MS-209 (Fig. 10), a quinolone-derivative that
blocks P-glycoprotein and multidrug resistance-associated
protein-1, has been reported as a SMS inhibitor [32].
Tricyclodecan-9-xanthogenate (D609, Fig. 10) was first
reported as an inhibitor of phosphatidylcholine-specific phos-
pholipase C from Bacillus cereus [33,34]. Moreover, it has been
reported that D609 also inhibits SMS in different cell types [35–
37]. However, the xanthate group is chemically unstable in
solution and is readily oxidized. Recently, synthesis and activity
of chemically stable S-(alcyloxymethyl) analogues of D609
have been reported. Among them, the pivaloyloxymethyl
analogue (D609 prodrug in Fig. 10) inhibited SMS more
efficiently than D609 in cells [38].
SM hydrolysis can be carried out by isoforms of sphingo-
myelinase (SMase), of which at least five isotypes have been so
far described. Most mammalian cells are capable of signalling
through the SM pathway, which can be activated both by
receptor ligands (TNF, interleukines) and stress (UV, oxidants,
radiation) [39]. SM hydrolysis by SMases produces phosphor-
ylcholine and the intracellular effector Cer. The former is
released into the aqueous environment, while Cer diffuses
within membranes, acting as a second messenger. Generation of
Cer in various cellular systems is currently recognized as critical
to the initiation of vital cellular processes such as differentia-
tion, cell proliferation and apoptosis.
SMases differ in their catalytic properties, subcellular
location and probably in their mode of regulation. Acid
SMase catalyzes the lysosomal degradation of SM. Inherited
deficiencies of acid SMase activity result in various clinical
forms of the Niemann–Pick disease, which are characterised by
massive lysosomal accumulation of SM [40]. Most of the acid
SMase is lysosomal, but an alternately spliced Zn-dependent
secretory form exists [41]. This second form is differentially
glycosylated and processed, and is believed to function in
inflammatory processes, including atherogenesis [42]. It is
secreted by macrophages, human skin fibroblasts, and human
vascular endothelial cells and is the only SMase responsible for
an extracellular hydrolysis of SM [43,44]. Recently, it has been
suggested that secreted SMase may play a critical role in the
development of apoptosis and organ failure in sepsis [45]. On
the other hand, neutral SMase is a Mg-dependent enzyme
located in plasma membranes [46]. In addition, a Mg-
independent neutral SMase is also found in cytosol [47], and
Fig. 9. Biosynthesis of SLs from Cer.
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tract [48].
Several physiological inhibitors of acid SMase have been
described. Thus, Kolzer et al. reported L-α-phosphatidyl-D-myo-
inositol-3,5-bisphosphate (PtdIns3,5P2) as a specific acid SMase
inhibitor (Ki 0.53 μM.) [49], and Testai et al. showed that L-α-
phosphatidyl-D-myo-inositol-3,4,5-triphosphate (PtdIns3,4,5P3)
is a non-competitive inhibitor of acid SMase from human
oligodendroglioma cells, with an IC50 value of 3 μM [50]. These
results provide some insights into the structural features required
for the selective, efficient inhibition of acid SMase (i.e. the 3-
phosphoinositide moiety may be critical) and may also be used as
starting point for the development of new potent acid SMase
inhibitors [50]. Recently, ceramide-1-phosphate (CerP) [51] and
sphingosine-1-phosphate (SphP) [52] have also been described
as physiological inhibitors of acid SMase in intact macrophages.
However, different mechanisms of action have been unveiled for
both inhibitors [53]. CerP also inhibited acid SMase in cellFig. 10. SMS inhibitors.homogenates, whereas SphP was only active in intact cells [52].
On the other side, glutathione (GSH) has been shown to be an
inhibitor of neutral SMase in a dose-dependent manner at
physiological concentrations with a greater than 95% inhibition
observed at 5 mMGSH [54]. Since GSH depletion is observed in
a variety of cells in the process of cellular injury and apoptosis,
these studies suggest that this may be an important mechanism
for activation of neutral SMase. It is worth noting that this
mechanism links oxidative stress and signalling through products
of SM hydrolysis [55].
There are a number of compounds, structurally unrelated to
SM, that have found application as SMase inhibitors. This is the
case of desipramine, SR33557, NB6, C11AG and GW4869
(Fig. 11).
Desipramine has been frequently used as a selective acid
SMase inhibitor. This compound, and possibly also other
similarly acting tricyclic antidepressants, induce proteolytic
degradation of acid SMase [56] by interfering with the binding
of the enzyme to the lipid bilayers and thereby rendering it
susceptible to proteolytic cleavage by lysosomal proteases [57].
Compound SR33557 is also an specific acid SMase inhibitor
(72% inhibition at 30 μM) [58]. This compound avoids apoptosis
induced by TNF inML-1a cells. Recently, NB6 has been reported
as an inhibitor of the SMase gene transcription [59] and it has
been used in in vivo experiments to propose that activation of the
plasmatic isoform of acid SMase may play a critical role in the
development of apoptosis and organ failure in sepsis [45].
Amtmann et al. described a series of new guanidinium derivatives
as inhibitors of neutral SMase. Lipophilicity was found to be
correlated with the inhibitory potential of the compounds and the
undecylidene aminoguanidine C11AG (Fig. 11) was the most
Fig. 11. Inhibitors of SMase.
1963A. Delgado et al. / Biochimica et Biophysica Acta 1758 (2006) 1957–1977active [60]. Collagen induced arthritis in mice could be prevented
and/or alleviated by C11AG treatment [61]. Compound GW4869
(Fig. 11) was discovered during a high throughput screening on
Mg2+ dependent neutral SMase. This compound acted as a
noncompetitive inhibitor with the substrate SM (IC50: 1 μM) and
exhibited significant and specific inhibitory activity with no or
minor inhibitory activity versus other hydrolytic enzymes, such
as bacterial phosphatidylcholine-PLC and bovine protein
phosphatase 2A. Importantly, GW6948 showed no inhibition
of the human acid SMase [62].
On the other hand, several compounds isolated from natural
sources exhibit interesting inhibitory activities against SMases.Fig. 12. Natural and synthThis is the case of scyphostatin (Fig. 12), a competitive inhibitor
(IC50: 1 μM) of neutral SMase, isolated from the mycelial
extract of Trichopeziza mollissima [63,64] Other SMase
inhibitors of natural origin are Macquarimicin A (IC50
146 μM for neutral SMase and 616 μM for acidic SMase)
[65], Alutenusin, a non-competitive inhibitor of neutral SMase
[66], Chlorogentisylquinone [67], Manumycin A (Fig. 12), an
irreversible specific inhibitor of neutral SMase [68], and α-
Mangostin, an acidic SMase inhibitor isolated from the
microorganism Garcinia speciosa [69].
Based on the inhibitory activity of scyphostatin, different
analogues have been designed. The first one was spiroepoxide 1etic SMase inhibitors.
1964 A. Delgado et al. / Biochimica et Biophysica Acta 1758 (2006) 1957–1977(Fig. 12), an irreversible and specific neutral SMase inhibitor
[70]. The primary hydroxyl group seems crucial for enzyme
inhibition, since a drastic decrease on the inhibitory activity was
observed after its replacement by H or phenyl groups [71]. Later
on, several analogues sharing the epoxy and cyclohexenone
structural features of Scyphostatin and Manumycin A have been
synthesized [72] and tested. Thus, compounds 2 and 3 (Fig. 12)
turned out to be selective irreversible inhibitors of neutral
SMase. Preliminary structure–activity studies suggested that the
presence of the cyclohexenone moiety was crucial for the
activity [68]. On the other hand, Pitsinos et al. reported the
preparation and inhibitory SMase activity of analogues 4–6 (Fig.
12), which lack the epoxy moiety. Compounds 4 and 6 were
found to be irreversible neutral SMase inhibitors, while
compound 5 was a weak inhibitor. As in the spiroepoxide
analogues, the presence of a primary hydroxyl group increases
enzyme inhibition, whereas an unsaturated side chain con-
tributes to a higher affinity for neutral SMase. Furthermore, the
epoxy moiety seems not to be a strict requirement for enzyme
inhibition [73]. In this context, compound 7 (Fig. 12), lacking
the epoxy function of the natural congener, has been reported as
the first scyphostatin analogue with a reversible neutral SMase
inhibitory activity [74]. Claus et al. also described the neutral
SMase inhibition by this new analogue in several in vivo test
systems (monocytes, macrophages, hepatocytes) by monitoring
its antiapoptotic effects and the inversion of phorbol ester-
induced translocation of green fluorescent protein labeled kinase
(protein kinase C-alpha) [74]. Recently, irreversible inhibition of
neutral SMase by a new family of compounds, named
sphingolactones, has been reported. Compounds with a
saturated butyrolactone (8–9) were better inhibitors than the
corresponding unsaturated analogues (10–11), and (2E,4E)-
hexadienoic acid derivative 8 was the most active [75].
Lister et al. [76] prepared sphingomyelin analogues differing at
the C-1 or C-3 position of the Sph backbone, which were tested
against neutral and acid SMase. Compounds modified at the C-1
position were not active, whereas the 3-O-methyl(compound 12,
Fig. 13) and the 3-O-ethylsphingomyelin analogues were selective
inhibitors of neutral SMase, with IC50 values of 50 μM and
140 μM, respectively. On the other hand, Hakogi et al. [77]
synthesized the sphingomyelin carbon analogues 13 (Fig. 13),
which showed moderate inhibitory activity toward neutral SMaseFig. 13. SM analogues afrom B. cereus (IC50=120 μM for n=1 and 78 μM for n=2).
Taguchi et al. [78] described the synthesis and activity of simplified
SM analogues with improved solubility and higher hydrolytic
stability. These goals were achieved by shortening the N-acyl
group, replacing the phosphodiester moiety by an ester or
carbamate function and using a dialkylamino or pyridyl group as
the trimethylammonium unit surrogates. Among them, carbamate
analogues of general structure 14 (Fig. 13) were good inhibitors of
neutral SMase, with IC50 values of 2–80μM.Moreover, carbamate
15 prevented Cer generation and apoptotic neuronal cell death in a
model of ischemia based on organotypic hippocampal slice cultures
[79].
On the other hand, Yokomatsu et al. [80] reported the
synthesis and activity of the CerP difluoromethylene analogues
16 (Fig. 13), in which the alkenyl chain of the parent sphingoid
base and the phosphate moiety were replaced by a phenyl group
and an isosteric difuoromethylenephosphonic acid, respectively.
The diastereomeric mixture showed a non-competitive neutral
SMase inhibition in bovine brain microsomes with an IC50 of
400 μM.
In addition, single enantiomers 16, ent-16 and the deoxyana-
logue 17 (Fig. 13) were also evaluated. The deoxyderivative 17
(IC50=181 μM) was found to be 2-fold more potent than 16,
which demonstrated that the 3-OH group is not critical for neutral
SMase inhibition. On the other hand, neutral SMase inhibition
significantly increases in analogues with unnatural configuration
on the sphingoid base. Thus, ent-16 (IC50=99 μM)was ca. 4-fold
more potent than 16. This trend was even more striking with
deoxy derivatives (17 vs. ent-17), since ent-17 (IC50=3.3 μM;
Ki=1.6 μM) was found to be ca. 60-fold more potent than 16.
These results reveal that the stereochemistry of the sphingoid
chain backbone is critical for interaction with the enzyme. The
mode of inhibition for ent-17 was determined to be non-
competitive. This analogue is also a good acid SMase inhibitor
from bovine brain lysosomes, showing a 48% inhibition at
3.3 μM concentration [81].
3.2. Ceramidase inhibitors
Catabolism of ceramide occurs by the action of CDases,
which hydrolyze the amide bond to yield the Sph moiety and
fatty acids. According to their pH optima for activity, CDasess SMase inhibitors.
Fig. 15. Inhibitors of CDases.
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CDase is localized in the lysosomes and its defect causes
Farber's disease [82–84]. Neutral CDases are localized in the
endoplasmic reticulum and the mitochondria and they have
been reported in several species [85–90]. Finally, alkaline
CDases have also been found in different organisms from
bacteria [91–93] to yeast [94,95] and mammals [96,97].
Several inhibitors of the neutral/alkaline [98,99] and the
acidic CDase [100–103] have been reported. The former
include the Cer analogue (1S,2R)-D-erythro-2-(N-myristoyla-
mino)-1-phenyl-1-propanol (D-MAPP) (Fig. 14) [98], which
has been extensively used in basic studies. From the chemical
standpoint, its enantiomer does not inhibit the neutral CDase,
but it undergoes a time- and concentration-dependent N-
deacylation to an extent similar to that observed with N-
hexanoylsphingosine [98].
The structural requirements of Cer and Sph analogues as
mitochondrial CDase inhibitors were investigated by Usta et al.
[99]. This enzyme was inhibited by all Sph stereoisomers, as
well as by N-methyl-D-erythro-sphingosine, D-erythro-sphinga-
nine, D-erythro-4,5-dehydrosphingosine (Fig. 14), (2S)-3-keto-
sphinganine, the three diastereoisomers of natural Cer and
D-erythro-N-hexadecylcarbamoylsphingosine (Fig. 14). Less
potent inhibitors included (2S)-N-hexadecanoyl-3-ketosphingo-
sine and N-octadecylsphingosine (Fig. 14). The N-octadecyl-
sphingosine and the urea analogue are competitive inhibitors. In
the same study, 1-O-methyl-D-erythro-sphingosine, (cis)-D-
erythro-sphingosine, (2S)-3-ketosphingosine, (2S)-3-ketodehy-
drosphingosine and N,N-dimethyl-D-erythro-sphingosine were
found to be weak inhibitors. These studies concluded that the
primary and secondary hydroxyl groups, the C4–C5 trans
double bond, and the NH-protons from either the amide or the
amine are required for enzyme inhibition. N-oleoylethanola-
mine (NOE, Fig. 14) is the acidic CDase inhibitor most
extensively used in cell biology studies, despite having a weak
potency (0.5 M) and poor selectivity [104]. From a chemical
standpoint, NOE can be regarded as an N-oleoylsphingosine
analogue arising from formal removal of the 1-hydroxy-2-
hexadecyl moiety. In contrast to NOE, N-leoylsphingosine is a
substrate of acidic CDase [105], which suggests that chemical
manipulation of the N-oleoylsphingosine framework might be a
suitable approach to the discovery of new acidic CDase
inhibitors. In agreement with this idea, several members of aFig. 14. Inhibitors of thfamily of C2 substituted NOE analogues showed a higher acidic
CDase inhibitory potency than NOE [106].
Other acidic CDase inhibitors include (1R,2R)-2-(N-tetrade-
cylamino)-1-(4-nitrophenyl)-1,3-propanediol (AD2646) [102]
and (1R,2R)-2-(N-tetradecanoylamino)-1-(4-nitrophenyl)-1,3-
propanediol (B-13) [100,101,103] (Fig. 15). Both compounds
suppress acid CDase activity with good potencies and the activity
of the neutral/alkaline isoform is affected only slightly. The
mechanism of inhibition by these compounds is not known. In
recent articles [106,22], the first family of mechanism-based
inhibitors of the acid CDase with potencies in the low μM range
was reported (compounds GT – Fig. 15 – and GT85, GT98. and
GT99 –Fig. 7) These compounds, which bear an α-ketoamide
unit (Fig. 15), have a good selectivity against acidic CDase in
vitro, since inhibition of neutral CDase requires around 20-fold
higher concentration.
3.3. Inhibitors of glucosylceramide biosynthesis and
catabolism
Glycosylation of Cer at the C1(OH) position provides
glycosphingolipids (GSLs), a wide structural family of cell
membrane components that plays important roles in biological
systems. They differ in the nature and the number of sugar units
linked to the Cer scaffold. As depicted in Fig. 16, the
biosynthesis of most GSL in mammals starts in the Golgi
complex with glucosylation of Cer. In this process, catalyzed by
glucosylceramide synthase (GlcCerS) (UDP-glucose:N-acyl-
sphingosine glucosyltransferase), the α-glucoside residue is
transferred from UDP-glucose to Cer with inversion of
configuration at the anomeric center of the sugar.e neutral CDases.
Fig. 16. Biosynthesis and catabolism of GlcCer.
1966 A. Delgado et al. / Biochimica et Biophysica Acta 1758 (2006) 1957–1977The initially formed glucosylceramide (GlcCer) serves as
starting building block for the synthesis of complex GSLs.
Thus, condensation of a galactose unit by means of a
galactosyltransferase leads to lactosylceramide (LacCer), a
starting point to the biosynthesis of all the hitherto reported
GSLs series [107].
The molecular architecture of GSLs as membrane compo-
nents requires an extracytosolic disposition with their hydro-
philic carbohydrate head groups oriented towards the outer
leaflet of the plasma membrane. In this context, GSLs play a
protective role in the cell against chemical and mechanical
damage. In addition to these mechanical properties, GSLs are
expressed as complex patterns, which have been accepted to take
active part in processes such as cell adhesion, cell growth
regulation, and differentiation. This “communication role” of
GSLs has emerged since the recognition of lectins as
complementary carbohydrate binding proteins, and the impli-
cation of cell surface glycolipids as physiologically relevant
lectin ligands in cell–cell recognition systems [108]. GSLs also
play important roles within cellular membranes, where they
form microdomains (“rafts”), which can regulate the activity of
some receptors in the plasma membrane, and hence signal
transduction [109].
While Cer biosynthesis is catalyzed by membrane-bound
enzymes at the cytosolic face of the endoplasmic reticulum
(ER), formation of GlcCer takes place at the cytosolic face of
the Golgi apparatus, and higher gangliosides are biosynthesized
at the luminal face. GSLs are then transported to the cell
membrane by means of exocytosis mechanisms from the Golgi
[107]. GSL catabolism takes place in the lysosomes, which are
specialized cell compartments where glycon-specific, pHFig. 17. Inhibitors of GlcCerSoptima glycosidases hydrolyze GSLs, arising from endocytosis
from cell membranes, to the corresponding monosaccharides
and Cer, which are mostly recycled in the cytosol. In the case of
GSLs with short oligosaccharide chains, the lipids to be
degraded are no longer accessible to hydrolases since they are
still embedded in the lipid bilayer structure of the parent cell
membrane. In this case, the participation of the so-called
“sphingolipid-activator proteins” (SAP or saposines) is re-
quired. It is widely accepted that SAP play an essential role by
presenting the oligosaccharide to the specific glycosidase by
“lifting” the glycolipid from the hydrophobic membrane
environment [110].
Metabolic disorders of GSL metabolism produce glyco-
sphingolipidoses, which a rare group of inherited diseases
having diverse, often neurodegenerative, and severe phenotypes
[1]. They are caused bymutations in catabolic enzyme genes that
reduce the catalyst efficiency giving rise to increased lysosomal
storage products. As it will be discussed below (see Sections
3.3.1 and 3.3.2), recent advances in the treatment of some of
these diseases have been achieved through direct intervention on
particular key enzymes involved in GSL biosynthesis and/or
degradation.
Catabolism of GlcCer (Fig. 16) can take place both at
lysosomal and non-lysosomal levels. In the first case, gluco-
sylceramide β-glucosidase (GlcCerase or glucocerebrosidase) is
responsible for the hydrolysis of GlcCer into Cer and glucose, a
process that requires the participation of the sphingolipid-
activator protein SAP-C (see above) [111]. On the other side, the
existence of a non-lysosomal glucosylceramidase near the cell
surface has also been documented [112]. This enzyme is an
integral membrane protein that shows different specificity(modified Cer analogues).
Fig. 18. Inhibitors of GlcCerS derived from the Sph backbone.
Fig. 20. Irreversible inhibitors of GlcCerase.
1967A. Delgado et al. / Biochimica et Biophysica Acta 1758 (2006) 1957–1977towards substrates and inhibitors, as compared with the
lysosomal enzyme (Section 3.3.2) [113].
The only known enzyme inhibitors of GSL biosynthesis at
the Cer level are restricted to the glucosylation step (catalyzed
by GlcCerS), its catabolic counterparts (GlcCerase and non-
lysosomal glucosylceramidase) and the galactosyltransferase
leading to LacCer from the initially formed GlcCer.
3.3.1. Inhibitors of glucosylceramide synthase
The enzyme glucosylceramide synthase (GlcCerS) is one of
the few glycosyltransferases for which efficient inhibitors are
known [114]. They belong to two different structural classes: (a)
those structurally related to Cer, and (b) synthetic analogues of
naturally occurring iminosugars, such as the α-glycosidase
inhibitor deoxynojirimycin (DNJ).
(a) Ceramide analogues: In the search for GSL biosynthesis
inhibitors, Vunnam and Radin [115] described a series of
ceramide analogues in which the unsaturated alkyl chain and the
amino moiety of the enzyme substrate were replaced by an
aromatic ring and an heteocyclic system, respectively (Fig. 17).
The most potent inhibitors were 1-phenyl-2-decanoylamino-3-
morpholino-propanol (PDMP) and its N-palmitoyl homologue
(PPMP). In all cases, the D-threo isomers were the most active
as competitive inhibitors of GlcCerS [116].Fig. 19. Iminosugars as GlcCerS inhibitors (in pareThese results boosted the synthesis of new analogues arising
from modifications of the aromatic and heterocyclic moieties.
Some of them, in particular compound hydroxy-P4, exhibited a
dramatic increase in potency and selectivity for the ceramide-
specific glucosyl transferase [117]. Moreover, the ethylene-
dioxy derivative (n=1, see Fig. 17) has recently been described
as a specific inhibitor of human GlucCerS in comparison with
enzymes from non-human origin [118]. Analogues combining
the heterocyclic moiety with the Sph backbone have also been
reported (Fig. 18) [119,120]. In all cases, it is worth mentioning
that the stronger inhibitors showed the non-natural (R,R)
configuration of D-threo sphingosine. These findings are
somewhat intriguing and pose serious doubts about the role of
these compounds as real substrate analogues. Nevertheless, it is
widely accepted that the protonated heterocyclic ring is able to
mimic the charged transition state of the enzyme/UDP–glucose
complex and that D-threo-PDMP is a reversible, mixed-type
inhibitor for ceramide but is uncompetitive for the nucleotide
sugar donor [116].
(b) Iminosugars and related compounds: Iminosugars
(polyhydroxypiperidines) comprise an important group of
inhibitors of glycosylation enzymes [121,122]. In particular,nthesis, % inhibition of GlcCerS at 200 μM).
Fig. 21. Polyhydroxypiperidine alkaloids and iminosugars as glucosylceramide hydrolase inhibitors (in parenthesis, non-lysosomal/lysosomal GlcCerase IC50 μM
inhibition); ni: no inhibition.
1968 A. Delgado et al. / Biochimica et Biophysica Acta 1758 (2006) 1957–1977N-butyldeoxynojirimycin (NBDNJ) and N-butyldeoxygalacto-
nojirimycin (NBDGJ) (Fig. 19) have shown inhibitory activity
against GlcCerS [123,124].
Despite having been described as sugar analogues acting as
transition state mimics of the glycosylation step, Butters et al.
have shown that inhibition of GlcCerS byNBDNJ is competitive
for Cer and non-competitive for UDP-glucose, which indicates a
structural mimicry of NBDNJ with Cer [125]. Structure–activity
studies carried out with iminosugars have evidenced the
importance of the N-alkyl chain for GlcCerS inhibition. Thus,
a chain length between 3 and 6 carbon atoms is required, while
longer chains increase inhibition, but also toxicity (see data in
Fig. 19). Modeling studies led to the assumption that NBDNJ
analogues substituted at the C(2) oxygen atom with a long alkyl
chain should be potent inhibitors due to their closer similarity
with Cer. However, experimental data did not confirm this
hypothesis [126]. Some iminosugars have been approved for theFig. 22. Analogy of isofagomine with the carbocationic intermediate generated
in the course of the hydrolysis of a β-glycosidic bond.treatment of certain sphingolipidoses. For example, NBDNJ
(miglustat, Zavesca®) [127,128] is currently used as a “substrate
reduction therapy” (SRT) drug for treating type I Gaucher
disease [129].
3.3.2. Inhibitors of glucosylceramide catabolic enzymes
As mentioned above, catabolism of GlcCer can take place by
the action of two β-glucosidases (glucosylceramide hydrolases)
that differ in their location and sensitivity towards selective
inhibitors. Thus, D-gluconolactone is a competitive inhibitor of
the non-lysosomal glucosylceramidase [112,113] but not of
lysosomal GlcCerase, for which some irreversible inhibitors are
known, such as, for example, conduritol B epoxide (CBE)
[130,131,113], cyclophellitol [132], and conduritol B aziridine
(CBA) [133] (Fig. 20).
Irreversible GlcCerase inhibitors have been used to gain in-
sight into the structure of the enzyme active site [130,131,134],
as well as pharmacological tools to induce animal models ofFig. 23. Isofagomine analogues with an alkyl chain on C6 position. GlcCerase
inhibition (IC50, nM) is shown in parenthesis. The postulated interaction model
with GlcCerase active site is depicted at the bottom.
Fig. 24. GlcCer imino linked analogues of valienamine and validamine.
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most GlcCerase inhibitors are competitive inhibitors and the can
be classified into three different families:
(a) Polyhydroxypiperidine alkaloids and iminosugars: The
polyhydroxypiperidine alkaloids DNJ [136–141] and castanos-
permine [142,143] (Fig. 21) have been described as GlcCerase
inhibitors by their structural similarity with the putative oxocarbe-
nium ion that develops in the course of the hydrolysis step.
In a classical work [113], a series of N-alkyl substituted DNJ
analogues were reported as GlcCerase inhibitors. Some of them,
specially those bearing a N-alkyl spacer and a large hydropho-
bic group, showed activities at nanomolar concentrations
against non-lysosomal GlcCerase (Fig. 21). In this case, the
hydrophobic groups were designed to favour the interaction
with the cell membrane, taking into account the enzyme
location (see above). More recently, some N-alkylated DNJ
analogues have been described as chemical chaperones of
GlcCerase, increasing its cellular activity by assisting on the
proper folding of the enzyme in the course of its maturation
process [144]. Among them, N-nonyldeoxynojirimycin
(NNDNJ) [145], (Fig. 21) and NBDNJ [146] (Fig. 19) have
shown promising chaperone effects on GlcCerase in different
cell studies. These findings offer a new potential therapeutic
alternative for the treatment of Gaucher disease, specially the
neuropathic variants, in addition to the substrate reduction
therapy (SRT, see above) or the enzyme replacement therapy
(ERT), which consists on the intravenous administration of the
deficient enzyme [147]. Recombinant GlcCerase (Imiglucerase,Fig. 25. NOV derivatives as GlcCerase inhibitors (in parentCerezyme®) is currently used in Gaucher disease for the
treatment of non neurological variations [148].
(b) Isofagomine analogues: Isofagomine, a synthetic ana-
logue of the alkaloid fagomine (Fig. 22), has been described as a
general inhibitor of β-glycosidases [149–151]. It was designed
taking into account its close geometric and electronic
similarities with the carbocationic intermediate that develops
in the first step of the β-glycosidic bond hydrolysis.
Very recently, some isofagomine analogues bearing an alkyl
chain on the C6 position have been described as selective
GlcCerase inhibitors [152,153]. This finding led the authors to
suggest the presence of a hydrophobic domain close to the
GlcCerase active site. According to this hypothesis, binding
interactions would be reinforced by an ionic bond between the
protonated heterocyclic amine with one of the acidic residues
(Glu340) at the enzyme's active site. This is consistent with the
observation that the corresponding N-alkyl derivatives were
markedly less potent inhibitors (Fig. 23). Some of these
analogues have also shown interesting chaperone activity on
GlcCerase with potential application for the treatment of
Gaucher disease (see above).
(c) Aminocyclitols: an important group of GlcCerase
inhibitors belong to this family of compounds. First reports
dealt with GlcCer imino linked analogues in which the
glucoside moiety was replaced with the aminocyclitol frame-
work present in the natural product β-valienamine and its
saturated analogue β-validamine (Fig. 24) [154,155]. Interest-
ingly, both Z and E isomers behaved as potent and selective
GlcCerase inhibitors, whereas β-validamine analogues were
less potent [154].
Simpler N-alkyl derivatives of β-valienamine [155] were
also strong GlcCerase inhibitors, the N-octyl derivative (N-
octyl-β-valienamine: NOV) being the most potent of the series.
In a later work [156], N-alkyl and N-acyl derivatives of NOV
were also synthesized and tested as GlcCerase inhibitors in
order to elucidate the role of the hydrophobic portion around the
nitrogen atom (Fig. 25). Although the latter lacked inhibitory
activity, the former analogues were strong GlcCerase inhibitors.
The same authors also tested a series of PDMP analogues
containing the β-valienamine and β-validamine moieties [157].
Some of them showed a strong inhibitory activity, as shown in
Fig. 26. More recently, a moderate GlcCerase activity has beenhesis, IC50 GlcCerase nM inhibition). ni, not inhibitor.
Fig. 26. Valienamine and validamine analogues as GlcCerase inhibitors (in parenthesis, IC50 GlcCerase μM inhibition).
1970 A. Delgado et al. / Biochimica et Biophysica Acta 1758 (2006) 1957–1977described for the 4-O-(β-D-galactopyranosyl) derivative of β-
valienamine [158] (Fig. 26).
Finally, a series of new inosamine derivatives have recently
been described as selective GlcCerase inhibitors (Fig. 27).
Interestingly, among the two diastereomeric series of analogues
described in that work, only those of the C1 series showed a
marked inhibitory activity against recombinant GlcCerase [159].
As already mentioned for the above families of GlcCerase
inhibitors, some N-alkyl β-valienamine derivatives are able to
increase the enzyme activity through a chaperone effect. This is
the case of NOV (see structure in Fig. 25), which gives rise to an
increase on the enzyme activity when applied to cultured
fibroblast cells bearing certain mutated enzymes with low
residual activities [160].
Finally, biosynthesis of complex gangliosides starts with
formation of lactosyl ceramide (LacCer) by galactosydation of
GlcCer by means of a galactosyltransferase (see Fig. 16). A
GlcCer analogue bearing an epoxide group on the C4 position
of the Glu moiety has been described as an irreversible inhibitor
of this enzyme in chick embryos cultured neurons [161].
3.4. Ceramide kinase inhibitors
Although some sphingosine kinase (SphK) inhibitors are
known to modestly inhibit ceramide kinase (CerK) at high
concentrations in vitro [162], the first specific and effective
CerK inhibitor has been reported only recently [163]. This
compound (K1) is an olefin isomer of the SphK inhibitor F-
12509A (see Fig. 29). In vitro kinase assays demonstrated that
K1 effectively inhibits CerK without inhibiting either SphK or
DAG kinase. The compound is also active in RBL-2H3 cells, inFig. 27. Inosamine derivatives as GlcCerase inhibitors (in parenthesis, IC50
GlcCerase μM inhibition).which it reduces cellular CerP levels and suppresses IgE/
antigen-induced mast cell degranulation.
4. Biosynthesis and metabolism of sphingosine-1-phosphate
Sphingosine-1-phosphate (SphP) is involved in the regula-
tion of many cellular functions [164,165]. There is evidence that
SphP acts as an intracellular second messenger involved the
regulation of calcium homeostasis and suppression of apoptosis.
Interest in SphP has increased enormously after the discovery of
its role as extracellular ligand for specific G protein-coupled
receptors known as the EDG-1 or SphP receptors family [166].
SphP is synthesized from Sph and ATP by the action of SphK
[167], for which two different isoforms are known: SphK1
[168,169], and SphK2 [170]. They differ in their tissue distribution
and cellular location. Interestingly, the SphP generated by the
action of each kinase gives rise to opposite biological effects
[171]. Compared with SphK1, SphK2 contains two mostly
unrelated aminoacid sequences, one at the amino terminus and
the other one in the middle of the protein chain.
Dephosphorylation of SphP to Sph is promoted by different
lipid phosphatases [172], including some specific SphP
phosphohydrolases [173,174]. The exact role played by these
phosphohydrolases in sphingolipid signalling is not well known
[175] and inhibitors for these enzymes have not been reported.
4.1. Inhibitors of sphingosine kinase
The first inhibitors described for SphK were the threo diaster-
omers of Sph as well its saturated counterpart, D,L-threo-
dihydrosphingosine (DHS or safingol) (Fig. 28) [176]. Since
DHS was slightly more potent than threo-sphingosines, it was
subsequently used in different studies involving SphP signal-
ling. Interestingly, DHS is a competitive inhibitor for SphK1,
being a substrate for SphK2 [170]. N,N-Dimethylsphingosine
(DMS) (Fig. 28) is an even more potent inhibitor, which has
been widely used in studies involving SphK and has become theFig. 28. Inhibitors of SphK.
Fig. 29. Some SphK inhibitors of natural origin.
1971A. Delgado et al. / Biochimica et Biophysica Acta 1758 (2006) 1957–1977reference inhibitor for these enzymes. DMS is present in several
cancer cell lines and, although it was first described as a
phosphokinase C (PKC) inhibitor [177,178], this compound
was also found to inhibit SphK [179–181]. DMS is a non-
specific SphK inhibitor, competitive for SphK1 and uncompet-
itive for SphK2 with Ki's in the low micromolar range for both
enzymes. Some specific SphK inhibitors have been recently
described. Thus, Kim et al. [182] reported on some potent in
vitro SphK2 inhibitors among a family of amino alcohols with a
modified sphingoid core structure. Pyrrolidine analogue SG-14
was one of the most interesting, as it was nearly equipotent with
DMS on SphK2 at 50 μM, while almost inactive against SphK1
isoform.
A number of natural products with SphK inhibitory activity
have been isolated from different sources. For example, the
isochroman compounds of fungal origin S-15183a and S-15183b
(Fig. 29) inhibited SphK from rat liver with IC50 values of 2.5 and
1.6 μM, respectively [183]. In a screening for SphK inhibitors, 4-
amino-3-hydroxybenzoic acid esters B-5354a, B-5354b, and B-
5354c (Fig. 29) were isolated from a marine bacterium and found
to be SphK inhibitors with IC50 values of 21, 58 and 38 μM,
respectively [184]. In addition, B-5354c exhibits a non-
competitive SphK inhibition (Ki=12 μM) in human platelets.
In contrast, B-5354c was an uncompetitive inhibitor of both
SphK1 (Ki=3.7 μM) and SphK2 (Ki=2.2 μM) [185]. Experi-
ments using synthetic derivatives of B-5354c indicated that all
three functional groups, i.e., the long unsaturated aliphatic chain,Fig. 30. Synthetic Sand the 4-amino and 3-hydroxyl groups, are required for SphK
inhibition [186].
Compound F-12509A (Fig. 29), a new sesquiterpene
quinone isolated from a discomycete consisting of a drimane
moiety and a dihydroxybenzoquinone, inhibits SphK in a
competitive manner (Ki=18 μM) [187]. Latter studies [185]
revealed that F-12509A is a competitive inhibitor of both
SphK1 (Ki=4 μM ) and SphK2 (Ki=5.5 μM) enzymes.
Finally, a screening of chemical libraries has led to the
identification of some potent human SphK1 inhibitors,
structurally unrelated to the sphingolipid structure. Some of
these compounds exhibit SphK inhibitory activities in the
nanomolar range and high selectivity towards SphK in front of
other human lipid and protein kinases (Fig. 30) [188]. Kinetic
studies revealed that the compounds were non-competitive
inhibitors of the ATP-binding site of SphK1. No data are
available on the isoform selectivity of these compounds. Very
recently [189], compound SKi (Fig. 30) has been used to
demonstrate that sphingosine kinase modulates voltage-operat-
ed calcium channels activity in GH(4)C(1) cells by removing
inhibitory sphingosine. Likewise, Gamble et al. [190] have
reported that phenoxodiol (PXD), a synthetic analogue of
genistein, inhibits sphingosine kinase, and suggests that this
activity may account in part for the pro-apoptotic and
antiangiogenic properties exhibited by this compound in most
cancer cells. Finally, a recent article by the group of Cuvillier
[191] has showed that docetaxel and camptothecin inducedphK inhibitors.
Fig. 31. Inhibitors of SphPL.
1972 A. Delgado et al. / Biochimica et Biophysica Acta 1758 (2006) 1957–1977strong inhibition of SphK1 in vitro, with the subsequent
elevation of the ceramide/S1P ratio.
4.2. Inhibitors of sphingosine-1-phosphate lyase
The last step in the catabolic route of ceramide is the
retroaldolic cleavage of SphP to give ethanolamine phosphate
and 2-hexadecenal (Fig. 9). This reaction is catalyzed by
sphingosine-1-phosphate lyase (SphPL), a microsomal enzyme
which, like some other aldolases, requires pyridoxal phosphate
as coenzyme [192]. The first reported inhibitor of this enzyme
was the SphP analogue 1-desoxysphinganine-1-phosphonate
(Fig. 31), which is a competitive inhibitor of SphPL [193].
Using rat liver microsomes as enzyme source, Boumendjel and
Miller [194] reported that 2-vinylsphinganine-1-phosphate (Fig.
31) inhibited SphPL in vitro with an IC50 of 2.4 μM. The
stereochemistry of this compound is not defined.
Compound FTY720 (Fig. 31) is a synthetic Sph analogue that
was rationally designed by modification of myriocin (Fig. 2), and
is being investigated as immunosuppressive agent. This com-
pound is phosphorylated in vivo to its active form [195,196] by
SphK2 [197] and exerts its effects by targeting SphP receptors
[198]. In a recent article [199], Bandhuvula et al. have
demonstrated that FTY720 also inhibits SphPL activity in vitro
and show that treatment of mice with FTY720 inhibits tissue
lyase activity, without affecting either lyase gene transcription or
protein expression. The studies by Bandhuvula et al. raised the
possibility that inhibition of SphP cleavagemay account for some
effects of FTY720 on immune function and that SphPL may be a
potential target for immunomodulatory therapy.
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